Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01560507 · ClinicalTrials.gov registry record · Phase 2
Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants
A Phase 2 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01560507 is a Phase 2 study that was terminated before completion, run by Duke University. The registered enrollment target is 19 participants.
The verdict
NCT01560507, a Phase 2 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to ascertain: 1) the rate of smoking cessation obtained using an adaptive treatment algorithm developed in previous clinical trials, in order to calculate cost-effectiveness of the treatment; 2) the relationship between genotype and response to cigarette smoking cessation treatment.
Interventions
- DRUG varenicline (Chantix)
- DRUG bupropion (Zyban)
- DRUG nicotine patches
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01560507
The ClinicalTrials.gov registry entry for NCT01560507 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which varenicline (Chantix) is the first listed.
NCT01560507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01560507 about?
NCT01560507 is a clinical study titled "Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants". The purpose of this study is to ascertain: 1) the rate of smoking cessation obtained using an adaptive treatment algorithm developed in previous clinical trials, in order to calculate cost-effectiveness of the treatment; 2) the relationship between genotype and response to cigarette smoking cessatio...
What is the current status of trial NCT01560507?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2012-05. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01560507?
The interventions under investigation include: varenicline (Chantix) (DRUG), bupropion (Zyban) (DRUG), nicotine patches (DRUG).
Who is sponsoring clinical trial NCT01560507?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.